Frankfurt
01.10.25 | 08:01
0,055 Euro
-5,05 % -0,003
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,080 | 0,083 | 21:47 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18:48 | Mauna Kea Technologies Announces 2025 Half-Year Results | 170 | Business Wire | 32% Reduction in H1 2025 Current Operating Loss excluding [Non-cash] Share-based Payments Improvement Reflects Strict Expense Control and 17% U.S. Sales Growth1 Finalization of Safeguard Plan... ► Artikel lesen | |
| 22.09. | Mauna Kea Technologies Presents the Final Terms of its Safeguard Plan | 244 | Business Wire | Reduction of the Company's debt from €40 million to €12 million, spread over 10 years Capital increase of at least €5 million post-plan adoption, with the issuance of stock warrants (BSAs) to... ► Artikel lesen | |
| 18.09. | Mauna Kea Technologies and Endotherapeutics Announce Cellvizio First Australian Orders, Advancing CellTolerance Commercial Expansion | 285 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT) and Endotherapeutics, today announced that Cellvizio system has been included in the Australian Register of Therapeutic Goods... ► Artikel lesen | |
| 12.09. | Mauna Kea Technologies Unveils the Outlines of its Safeguard Plan to Ensure its Turnaround | 264 | Business Wire | Shareholders, holders of securities giving access to the capital, and creditors of Mauna Kea Technologies convened into classes of affected parties to vote on the safeguard plan
Regulatory News:... ► Artikel lesen | |
| 08.09. | Mauna Kea Technologies Announces Strong Advocacy from the American Foregut Society (AFS) for Broad Reimbursement Coverage from U.S. Commercial Payors for Cellvizio | 254 | Business Wire | New letter published by the AFS highlights Cellvizio's superiority to conventional tools for detecting pre-cancerous tissue and dysplasia
Regulatory News:
Mauna Kea Technologies (Euronext... ► Artikel lesen | |
| 08.09. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 199 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 29.08. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 479 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 28.07. | Mauna Kea Technologies Reports First Half 2025 Revenue | 426 | Business Wire | On Constant Currency Basis (CER), U.S. sales up +17% Y/Y in H1 and +23% in Q2 Record U.S. sales productivity despite ongoing safeguard procedure Total revenue down 5% amid weaker EMEA and... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 24.07. | Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership | 499 | Business Wire | Leveraging strong momentum for the CellTolerance® application, Mauna Kea Technologies is expanding into new geographies with high growth potential Regulatory clearance in Australia (TGA) expected... ► Artikel lesen | |
| 21.07. | Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. | 593 | Business Wire | 14th U.S. AI patent awarded complementing a comprehensive portfolio of AI-related intellectual property An ecosystem built around the Cellvizio® platform, enabling partners to develop advanced... ► Artikel lesen | |
| 15.07. | Mauna Kea Technologies Congratulates Stanford Health Care on Completing 100 Food Intolerance Cases with Cellvizio | 551 | Business Wire | Clinical team at Stanford Health Care achieved the CellTolerance 100-case milestone with the Cellvizio® platform in less than 6 months The CellTolerance® test offers IBS patients a way to detect... ► Artikel lesen | |
| 10.07. | Mauna Kea Technologies Extends Its Financial Horizon Beyond the Observation Period of the Safeguard Procedure | 779 | Business Wire | Bridge financing through the issuance of convertible bonds to Vester Finance and European investors for €1.8m Immediate receipt of the entire financing upon signing Cash runway extended to... ► Artikel lesen | |
| 10.07. | Mauna Kea Technologies Reaches Key Milestone in its Safeguard Procedure | 494 | Business Wire | Structuring of financing in progress to secure the safeguard period and support long-term development plan Authorization to implement the classes of affected parties proceeding, paving the way... ► Artikel lesen | |
| 07.07. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 282 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 387 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.06. | Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025 | 543 | Business Wire | All the resolutions proposed by the Board of Directors were adopted
Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and... ► Artikel lesen | |
| 02.06. | Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification | 611 | Business Wire | Cellvizio technology combined with AI outperforms human experts in pancreatic cyst risk stratification, a major breakthrough for patient management Results build on new CLIMB study data recently... ► Artikel lesen | |
| 21.05. | Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress | 463 | Business Wire | Ongoing Strategic Negotiations Towards a Licensing Agreement Strong Momentum for CellTolerance: Over 1,500 Procedures Completed, New Centers of Excellence Adopting the Technology, Including a... ► Artikel lesen | |
| 20.05. | Mauna Kea Technologies Announces the Availability of Preparatory Documents for the Combined General Meeting of June 5, 2025 and the Instructions for Participation | 1.217 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 06.05. | Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week 2025 | 934 | Business Wire | Over 75 physicians attended educational presentations about the breakthrough impact of needle-based Confocal Laser Endomicroscopy and AI on the diagnosis and treatment of pancreatic cystic lesions... ► Artikel lesen |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,107 | -2,73 % | Sernova Biotherapeutics Announces $13 Million Debt-to-Equity Conversion Eliminating Significant Financing Overhang | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - October 1, 2025) - Sernova Biotherapeutics (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH0) ("Sernova") a leading regenerative medicine company focused... ► Artikel lesen | |
| FAMICORD | 5,950 | 0,00 % | EQS-Adhoc: FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. erwirbt 100 % der Anteile an der Stammzellbank 'nOvum' spólka z ograniczona odpowiedzialnoscia, Warschau, Polen | EQS-Ad-hoc: FamiCord AG / Schlagwort(e): Fusionen & Übernahmen
FamiCord AG: Polski Bank Komórek Macierzystych sp. z o. o. erwirbt 100 % der Anteile an der Stammzellbank 'nOvum' spólka z ograniczona... ► Artikel lesen | |
| GERATHERM MEDICAL | 4,100 | +20,59 % | Geratherm Medical AG: Starkes Wachstum im ersten Halbjahr und operatives Break-even; KAUFEN bestätigt. | Geratherm verzeichnete im ersten Halbjahr 2025 ein starkes Wachstum: Die vergleichbaren Umsätze stiegen um 13,2 % gegenüber dem Vorjahr und sequenziell um 15,4 %. Getrieben wurde dieses Wachstum von... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,677 | +0,06 % | Plus Therapeutics Inc.: Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer | HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed... ► Artikel lesen | |
| MEDICLIN | 3,080 | -1,91 % | EQS-News: MEDICLIN AG: MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025 | EQS-News: MEDICLIN AG
/ Schlagwort(e): Halbjahresbericht/Halbjahresergebnis
MEDICLIN zieht positive Zwischenbilanz für das erste Halbjahr 2025
31.07.2025 / 13:13 CET/CEST
Für... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,728 | -1,62 % | Atossa Therapeutics appoints Janet Rea as SVP of R&D | ||
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting | -- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc.... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,480 | -100,00 % | Sonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 | BOULDER, COLORADO / ACCESS Newswire / September 25, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized... ► Artikel lesen | |
| VERU | 3,820 | +1,60 % | VERU INC. - 8-K, Current Report | ||
| LIFEWARD | 0,700 | -1,55 % | Lifeward Ltd.: Lifeward Achieves CE Mark Approval for the ReWalk 7 Personal Exoskeleton | MARLBOROUGH, Mass. and YOKNEAM ILLIT, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform... ► Artikel lesen | |
| LIGHT AI | 0,124 | +9,73 % | Light: AI-Based Finance Platform Raises $30 Million Series A | ||
| MAVEN BRANDS | 0,001 | 0,00 % | Maven Brands Inc: Maven Brands to sell subdivided Lumby land for $3.5M | ||
| EKSO BIONICS | 5,320 | +7,26 % | Ekso Bionics Holdings, Inc.: Ekso Bionics Reports Second Quarter 2025 Financial Results | SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial... ► Artikel lesen | |
| IMUNON | 4,440 | +1,37 % | Imunon's Phase III-stage IL-12 gene therapy alters tumour microenvironment in ovarian cancer | ||
| SIEMENS HEALTHINEERS | 46,300 | +0,61 % | JEFFERIES stuft Siemens Healthineers auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Siemens Healthineers auf "Buy" mit einem Kursziel von 60 Euro belassen. Die am 5. November anstehenden Schlussquartalszahlen dürften es dem... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von -0,003 (-5,05 %) liegt der Kurs bei 0,055 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.